Filing Overview
Phathom Pharmaceuticals, Inc. filed a Form 8-K dated March 11, 2020. The filing reports amendments to its loan agreement, a subsequent $25.0 million term-loan draw, and executive compensation actions. The company is a clinical-stage pharmaceutical business developing vonoprazan.
Financing and Liquidity
- On March 11, 2020, the company amended its loan and security agreement with Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P.
- The company had previously borrowed $25.0 million under Term Loan A in May 2019 and had the right to borrow an additional $25.0 million under Term Loan B.
- On March 16, 2020, the company drew the full $25.0 million Term Loan B, increasing aggregate principal borrowings under the Term Loans to $50.0 million.
- The proceeds are intended to fund vonoprazan clinical development, working capital, and general corporate purposes, including pre-commercial activities.
- The loans bear interest at the greater of the Wall Street Journal Prime rate plus 1.75% or 7.25%.
- Interest-only payments are scheduled through May 31, 2021, subject to potential extensions. Thereafter, principal and interest are payable in equal monthly installments through the May 1, 2024 maturity date.
- The company must pay a final payment fee equal to 8.25% of the original principal amount of the Term Loans.
- As of March 16, 2020, the company stated that it was in compliance with applicable loan covenants.
Material Changes and Terms
- The interest-only period may be extended to December 31, 2021 if positive Phase 3 data in H. pylori infection is sufficient to support an FDA new drug application filing.
- The interest-only period may be extended to November 30, 2022 if positive Phase 3 data in both vonoprazan indications is sufficient to support an FDA new drug application filing.
- Each extension requires the company to have drawn the additional $25.0 million Term Loan B.
- The agreement contains customary affirmative and negative covenants, including restrictions on additional indebtedness, liens, acquisitions, dividends, asset transfers, and specified corporate transactions.
- Upon an event of default, outstanding amounts may bear interest at 4.00% above the otherwise applicable rate and may become immediately due and payable.
Executive Compensation
- The board approved 2019 cash bonuses of $23,091 for CEO Terrie Curran, $197,625 for CFO David Socks, $142,507 for COO Azmi Nabulsi, and $80,015 for Chief Business Officer Aditya Kohli.
- The board adopted a bonus plan with target bonuses equal to 50% of base salary for the CEO and CFO and 40% for the COO.
- Bonuses depend on corporate and individual performance. Corporate performance may produce a multiplier of up to 150%, and final payouts generally may not exceed 180% of target bonuses.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no revenue, profit, cash-flow, margin, or cash-balance data and does not provide formal financial guidance. The primary financing-related risks are the floating interest rate, required amortization beginning after the interest-only period, the final payment fee, covenant restrictions, and potential acceleration following an event of default. Extensions of the interest-only period depend on positive Phase 3 clinical results and the ability to support FDA filings.
Investor Verification Items
- Verify the complete amended loan agreement and the final payment fee calculation when filed as an exhibit to the March 31, 2020 Form 10-Q.
- Assess the company’s cash runway and planned use of the $25.0 million Term Loan B in subsequent periodic filings.
- Monitor Phase 3 vonoprazan results and whether they support the potential interest-only-period extensions or future FDA filings.
- Review subsequent filings for covenant compliance, interest-rate changes, and repayment obligations.
- Confirm the accounting treatment and timing of the approved 2019 executive bonuses and the new bonus plan.